Lenvima (lenvatinib) — United Healthcare
Differentiated thyroid cancer (DTC)
Initial criteria
- Diagnosis of differentiated thyroid cancer (DTC)
- Disease is locally recurrent, metastatic, progressive, or symptomatic
- Disease is radioactive iodine-refractory or ineligible
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Lenvima therapy
Approval duration
12 months